LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.
The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.
advertisement
AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Crowdfunding for medical bills sidesteps core problem, author says
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
